Search for Tradename: CLARINEX

Summary for Tradename: CLARINEX

Patents:	11
Applicants:	2
NDAs:	5
2009 Sales:	$181,215,000
Therapeutic Class:	Respiratory Tract Agents

Latest news for CLARINEX

Reportlinker Adds The Indian Pharmaceutical Industry: New Strategies in a Changing World

19 July 2010, 9:47 am

Start-up Assurance Biosciences Raises $1.2M While Working out of UT’s Biotech Commercialization Ctr. - cbl

8 July 2010, 8:24 pm

Courtesy of Yahoo News

Glossary

Applicant	Tradename	Generic Name	NDA	Approval Date	Type	RLD	Patent Number	Delist Req.	Patent Expiration
Schering	CLARINEX	desloratadine	021300	Sep 1, 2004	RX	Yes	6,514,520*PED	Y	Dec 1, 2018
Schering	CLARINEX	desloratadine	021300	Sep 1, 2004	RX	Yes	7,211,582*PED	Y	Jun 30, 2015
Schering	CLARINEX	desloratadine	021300	Sep 1, 2004	RX	Yes	7,214,683*PED	Y	Jun 30, 2015

Export available with Ultimate Plan subscription:

This preview shows a limited data set. Complete access is available with a Subscription

Paragraph IV activity for: CLARINEX

Drugname	Dosage	Strength	RLD	Submissiondate
desloratadine	Oral Solution	0.5 mg/mL	Clarinex Syrup	5/8/2008
desloratadine	Tablets	5 mg	Clarinex	6/21/2006
desloratadine and pseudoephedrine sulfate	Extended-release Tablets	5mg/240mg	Clarinex-D 24 Hour	6/21/2006
desloratadine	Orally Disintegrating Tablets	2.5 mg and 5 mg	Clarinex	6/21/2006

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:
2000 2001 2002 2003 2004
2005 2006 2007 2008 2009

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Follow DrugPatentWatch on Twitter

Bookmark or Share This Page ...